Search everything in EDGE ID⌘K
EDGE ID · signed in on this Mac
Grants 9 active · £9.19 M awardedsynthetic 1 overspend risk
| Ref | Funder | Title | PI | Value | Ends | Spent |
|---|---|---|---|---|---|---|
| MR/Y01842/1 | MRC | Urine ctDNA surveillance | Dr I. Hart | £1,240,000 | Mar 2029 | 31% |
| C61473/A29012 | CRUK | FGFR3 variant atlas | Dr K. Mensah | £684,000 | Sep 2027 | 58% |
| NIHR206114 | NIHR | Wearable post-op | Dr T. Ashdown | £1,480,000 | Jun 2028 | 22% |
| 226781/Z/24/Z | Wellcome | Evo 2 effect prediction | Dr R. Calloway | £2,100,000 | Dec 2029 | 14% |
| 10098412 | IUK | Edge fundus triage | Dr A. Rahman | £498,000 | Jan 2027 | 77% |
| EP/Z531902/1 | EPSRC | Sustainable GPU use | Dr F. Gallagher | £812,000 | Aug 2028 | 26% |
| MR/X0291/2 | MRC | Single-cell TME | Dr E. Kowalczyk | £905,000 | Feb 2027 | 84% |
| NIHR204551 | NIHR | AI cystoscopy | Dr O. Price | £1,120,000 | Oct 2027 | 49% |
| YCR-2025-07 | YCR | Faster pathway | Dr H. Reid | £356,000 | Apr 2027 | 62% |
Datasets 18 registered · SHA-256 checked nightly1 mismatch
| Dataset | Source | Records | Agreement | Checksum | Access |
|---|---|---|---|---|---|
| UK Biobank WGS 500k subset | UK Biobank | 48,210 | MTA 91827 | Matches | Approved |
| NIHR BioResource bladder | NIHR BioResource | 1,904 | DSA 2024-118 | Matches | Approved |
| Genomics England 100kGP cancer | GEL | 16,420 | Airlock only | In TRE | Researcher |
| TCGA-BLCA | GDC open | 412 | Open, dbGaP for BAM | Matches | Open |
| Leeds urology PTL 2019-26 | LTHT | 38,114 | DSA LTHT-0412 | Matches | Approved |
| DESP fundus archive | NHS DESP Leeds | 214,600 | DSA DESP-22 | Mismatch 3 | Approved |
| Wearable cohort PRJ-0391 | Own, consented | 1,050 | Consent v3.2 | Matches | Team |
| ClinVar 2026-09 | NCBI | 3.1 M | Public domain | Matches | Open |
| gnomAD v4.1 | Broad | 807,162 | ODbL | Matches | Open |
| COSMIC v100 | Sanger | 1.5 M | Academic licence | Matches | Licensed |
| TURBT WSI set | LTHT pathology | 1,840 | DSA LTHT-0377 | Re-hashing | Approved |
| Colonoscopy video frames | Hyper-Kvasir | 110,079 | CC BY 4.0 | Matches | Open |
| MedGemma QA reports | Own, synthetic | 2,400 | Internal | Matches | Team |
| Evo 2 benchmark variants | Own + ClinVar | 52,000 | Internal | Matches | Team |
| NMIBC RNA-seq | LTHT | 312 | DSA LTHT-0398 | Matches | Approved |
| Retinal OCT pairs | Moorfields | 6,210 | DSA MEH-1188 | Matches | Approved |
| Civo GPU usage logs | Own | 1.2 M | Internal | Matches | Team |
| Methylation cfDNA | LTHT | 220 | DSA LTHT-0402 | Matches | Approved |
Reproducibility re-runs independent re-run in a clean container · 41 this year1 not matching
| Re-run | Analysis | Published | Re-run | Δ | Result |
|---|---|---|---|---|---|
| RR-0098 | Hart 2025 · Table 2 sensitivity | 0.874 | 0.874 | 0.000 | Exact |
| RR-0097 | Hart 2025 · Fig 2 ROC AUC | 0.912 | 0.911 | −0.001 | Within tol. |
| RR-0096 | Mensah 2024 · FGFR3 VAF median | 0.31 | 0.31 | 0.00 | Exact |
| RR-0095 | Calloway 2026 · Evo 2 AUROC | 0.947 | 0.946 | −0.001 | Within tol. |
| RR-0094 | Rahman 2025 · DR sensitivity | 0.962 | 0.962 | 0.000 | Exact |
| RR-0093 | Reid 2025 · Fig 3B hazard ratio | 2.41 | 2.07 | −0.34 | Not matching |
| RR-0092 | Reid 2025 · Table 1 n | 312 | 312 | 0 | Exact |
| RR-0091 | Kowalczyk 2025 · UMAP clusters | 14 | 13 | −1 | Review |
| RR-0090 | Ashdown 2026 · HRV drop AUC | 0.81 | 0.81 | 0.00 | Exact |
| RR-0089 | Pillai 2026 · MedGemma F1 | 0.884 | 0.879 | −0.005 | Within tol. |
| RR-0088 | Price 2025 · polyp mAP50 | 0.702 | 0.698 | −0.004 | Within tol. |
| RR-0087 | Okafor 2025 · DMR count | 1,204 | 1,204 | 0 | Exact |
Ethics approvals HRA and REC · 6 studies1 lapsed
| IRAS | REC | Study | Approved | Ends | Amend. | Status |
|---|---|---|---|---|---|---|
| 331842 | 24/NW/0187 | Urine ctDNA surveillance | Mar 2024 | Mar 2029 | 2 | Valid |
| 318804 | 23/YH/0221 | AI-assisted cystoscopy | Nov 2023 | Oct 2027 | 1 | Valid |
| 342210 | 25/LO/0412 | Wearable post-op monitoring | Jan 2025 | Jun 2028 | 3 | Amend due |
| 309915 | 22/YH/0164 | Single-cell bladder TME | Jun 2022 | Dec 2026 | 4 | Expires 81 d |
| 327001 | 24/EM/0098 | Edge fundus triage | Feb 2024 | Jan 2027 | 1 | Valid |
| 298430 | 21/NE/0233 | Methylation cfDNA | Sep 2021 | Sep 2026 | 2 | Lapsed 27 d |
RR-0093 Fig 3B hazard ratioNot matching
PaperReid H et al. 2025 · Eur Urol OncolClaimHR 2.41 (95% CI 1.52-3.83)Re-runHR 2.07 (95% CI 1.28-3.35)GrantMR/X0291/2 · MRCDataNMIBC RNA-seq · DSA LTHT-0398Containersha256:7c41…e09a
Environment and data diff7 events differ
| Item | Published | Re-run |
|---|---|---|
| R | 4.3.1 | 4.3.1 |
| survival pkg | 3.5-5 | 3.5-5 |
| Seed | not recorded | 20251012 |
| Cohort filter | pT1 + pTa HG | pT1 + pTa HG |
| Events | 71 | 64 |
| Excluded | not listed | 7 lost follow-up |
Timeline
| Fri 14:02 Re-run queued by schedule |
| Fri 14:31 HR 2.07 · outside tolerance |
| 09:10 Jude traces 7 excluded patients |
| 10:44 Dr H. Reid notified |
Next decision
Openintegrity note IN-2026-014AskPI for exclusion listThenpin seed, re-run, compare
Open noteAsk PIPin env
Research integrity lead decides · no public statement
Tell Jude what you intend to do
JudeAI · Qwen 27B on Civo